Neglected Tropical Disease Treatment Market By Treatment Type (Drug Therapy {Antiparasitic, Antifungals, Antiviral Agents, Antibiotics}, Vaccination, Combination Therapy, Symptomatic Treatment, Supportive Therapies), By Disease Type (Dengue, Chagas Disease, Leishmaniasis, Lymphatic Filariasis, Schistosomiasis, Human African Trypanosomiasis, Onchocerciasis, Rabies, Soil-transmitted Helminths, Other), By Route of Administration (Oral, Parenteral, Topical), By End-User (Hospitals, Clinics, Research Institutes, Non-Governmental Organizations), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Neglected Tropical Disease Treatment market accounted for USD 4.08 Billion in 2024 and is expected to reach USD 6.73 Billion by 2035, growing at a CAGR of around 4.65% between 2025 and 2035. The Neglected Tropical Disease Treatment Market involves designing, manufacturing, and supplying treatment solutions for NTDs. Examples of NTDs are malaria, leishmaniasis, and Chagas diseases, which are prevalent among communities in the developing world.

This market is being driven by international health policy, pharma development, and partnership with WHO and DNDi. There are numerous barriers to implementing successful market strategies, such as the scarcity of healthcare facilities. However, the markets are still expanding as a result of increased awareness and a desire for innovations in delivery systems. It includes grants, contributions, and corporate activities that aim to increase access to and availability of critical medicines.

Report Scope:

Market Dynamics

Increased Global Health Initiatives for NTD Control by Governments and Organizations

The Neglected Tropical Disease Treatment Market has significant potential for development with increased activism from governments and organizations across the world. The global initiative comprises WHO's NTD Roadmap 2030, which aims to achieve its objectives through mass drug administration, vaccination, community education, and so on. These efforts are accompanied by further contributions from organizations like the Bill & Melinda Gates Foundation, which are launching treatment and healthcare infrastructure initiatives.

These projects provide hope to populations in endemic areas for both prevention and treatment. The former pharmaceuticals have identified access to affordable therapies as a defining area for collaboration between the pharmaceutical industry and public health stakeholders. This large-scale collaboration is addressing NTDs and global health as a whole, mitigation of socioeconomic impacts, and quality of life for people in endemic areas.

Rising Awareness and Advocacy for Disease Eradication in Endemic Regions Worldwide

The Neglected Tropical Disease Treatment Market is growing as awareness advocacy and disease control initiatives ignite the globe toward disease-free endemic areas. To guarantee that communities understand the consequences of NTDs, governments, health agencies, NGOs, and civil society organizations use social media marketing, community health promotion, and education.

They assist individual communities or nations with information concerning prevention, early detection, and treatment. Such advocacy has mobilized resources and policy change to improve the enshrinement of basic and advanced treatments and vaccines. Well-known personalities and world movements have reiterated this cry, which has prompted collaborative associations between drug manufacturers and health institutions. Collectively these are generating a wave-like impact, fashioning increased dynamism in tackling NTDs and lifting health parameters in needy areas.

Limited Access to Healthcare Infrastructure in NTD-Endemic Low-Income Regions

The Neglected Tropical Disease Treatment Market presents a significant challenge owing to insufficient access to health facilities for people living in poor, disease-prone countries. Notably, in rural places, medical facilities with experienced workers and diagnostic equipment are sometimes missing, making early detection and treatment challenging. In the context of NTDs, basic infrastructural requirements make NTD treatment and prevention even more difficult, putting millions of people at risk of the disease with little to no access to effective interventions.

Some attempts have been made to bring closure, and the world's leading organizations are currently working on mobile clinics, teleconsultation, and local vertical healthcare. Unfortunately, financing uncertainty and logistical problems continue to impede progress. Improving healthcare system capabilities is critical for ensuring equitable access to treatments and improving the lives of people living with NTDs in these underserved locations.

Collaborative Partnerships between Pharma Companies and Global Health Organizations for NTD Control

The Neglected Tropical Disease Treatment Market is on the ascent when it comes to inventive associations between pharmaceutical companies and global health organizations to address NTDs. With assistance from the World Health Organization, the Gates Foundation, and other global agencies, pharmaceutical companies such as GSK, Merck, and Sanofi are leading efforts in the discovery of better cures. Such partnerships do not only promote product and technological advances, but more importantly, they create options to make sure that life-sustaining treatments are available to those who are most in need.

They also play an important role in reaching out to more consumers, securing funding for clinical trials, and developing methods to make breakthrough therapeutic goods accessible and cheap. Resource sharing and collaboration have made it easier for pharmaceutical corporations and global health organizations to address diseases traditionally deemed unprofitable owing to disability gestation. It is an encouraging joint effort that is accelerating progress toward Goal 3, which is to eliminate the burden of neglected tropical diseases.

Emerging Technologies in Drug Delivery and Diagnostics for Better NTD Management

The Neglected Tropical Disease Treatment Market is witnessing a rise in technological advancement due to new advancements in the delivery of drugs and diagnosis. Innovations, for instance, in the area of the nanoworld and better drug delivery platforms are increasing the efficiency and accuracy of healing. These technologies allow for the development of controlled-release formulations that help reduce pill burden, and new assay technologies offer a better and faster diagnosis of the disease. This is revolutionizing the management of NTDs, especially in the hard-to-reach areas where access to healthcare is a major challenge.

Diagnostic tools like PoCT and PoC devices are supporting early diagnosis of contagious diseases, including leishmaniasis and Chagas diseases. Furthermore, data analytics powered by artificial intelligence and machine learning are the most significant developments that enable preventative forecasts and treatment procedures. Altogether, these advances are enhancing NTD management and revealing a new promising horizon for controlling these merciless diseases in terms of effectiveness.

Industry Experts Opinion

“The inclusion in the WHO’s list of NTDs is an important step, but not the final one. This recognition got noma and noma survivors the attention they deserve, but that attention needs to be maintained and translated into real measures to achieve its elimination. The global health community and donors must continue to prioritize treatment efforts and research to eventually see the end of noma worldwide.”

• Mark Sherlock, MSF Health Programme Manager.

"The training and support of young NTDs champions accelerate demand generation and resource mobilization for NTDs work. When looking at Zimbabwe, we are a youthful country, and our leaders should embrace the opportunity to meaningfully engage and collaborate with young people in the fight against NTDs. These Youth Champions can raise awareness about NTDs with their peers in schools, community centers, and on social media platforms."

• Mr John Dongo, a youth champion with Youth Combating NTDs (YCNTDs)

Segment Analysis

Based on Treatment Type, the Neglected Tropical Disease Treatment Market is classified into Drug Therapy, Vaccination, Combination Therapy, Symptomatic Treatment, and Supportive Therapies. The Neglected Tropical Disease Treatment Market is heavily reliant on pharmacological therapy, specifically antiparasitic, antifungal, antiviral, and antibiotics. In this sense, ivermectin is among the most often used antiparasitic medications, particularly in mass-use campaigns.

Vaccination is on the upswing, with vaccines like Dengvaxia for dengue fever and significant advances in rabies vaccines. Combination medicines are increasingly being used to treat people with different disorders. In locations with limited access to care, all contribute to patient comfort and recovery.

Based on Disease Type, the Neglected Tropical Disease Treatment Market is categorized into Dengue, Chagas Disease, Leishmaniasis, Lymphatic Filariasis, Schistosomiasis, Human African Trypanosomiasis, Onchocerciasis, Rabies, Soil-transmitted Helminths (STH), and Other. The Neglected Tropical Disease Treatment Market is significantly biased toward diseases like dengue, leishmaniasis, and lymphatic filariasis, which are endemic in tropical and subtropical climates.

Chagas disease and leishmaniasis are significant diseases active in South America and Asia, and people need to cure them. Lymphatic filariasis and schistosomiasis are still current problems in Africa. Donations for drugs are available for use in the fight against human African trypanosomiasis and onchocerciasis. Tropical and soil-transmitting helminthiasis is being focused on more and more due to its effects on the low-income group.

Regional Analysis

The Middle East and African Neglected Tropical Disease Treatment Market is developing, primarily due to growing awareness, global health activities, and expanding health budgets. Non-communicable tropical diseases, including leprosy, lymphatic filariasis, schistosomiasis, and soil-transmitted helminths, are still a burden to populations of developing nations, especially sub-Saharan Africa. The World Health Organization (WHO) and NGOs are funding the treatment and increasing the availability of access to medication. Though there are prospects for growth, there are various obstacles, like insufficient health facilities, political instability in some areas, and insufficient health infrastructures, all of which contribute to an inefficient supply chain. The market is supported by the continuous introduction of novel, cost-effective, and locally tailored medicines.

The Asia-Pacific Neglected Tropical Disease Treatment Market is growing as more people have access to healthcare facilities and governments take steps to combat disease spread. India and Indonesia are infested with diseases such as dengue, leishmaniasis, and filariasis. The examples include India employing combination therapy in the treatment of kala-azar and Japan designing new vaccines for dengue fever control. The area has also benefited from international partnerships like WHO-supported elimination programs on lymphatic filariasis. Many big pharma companies, such as Eisai and Novartis, are increasing their investment in the growth region, offering affordable access to therapies appropriate to the region.

Competitive Landscape

Major players operational in the Neglected Tropical Disease Treatment Market are GlaxoSmithKline (GSK), Pfizer Inc., Sanofi, Novartis AG, and Merck & Co., Inc. These companies are fully engaged in the development of new therapeutics and the usage of massive drug donations. WHO and DNDi provide a partnership for managing diseases like leishmaniasis, Chagas disease, and lymphatic filariasis. By developing and offering cheap treatments, cures, and precise targeting of certain diseases, these firms play a crucial role in combating neglected tropical diseases around the world. 

Other key players like Johnson & Johnson, Eisai Co., Ltd., Takeda Pharmaceutical Company, Bayer AG, and AbbVie Inc. These companies are improving the administration of drugs, supporting vaccination drives, and enhancing access to treatments for these diseases in endemic areas. These, in conjunction with the partnerships and regional outreach programs, expand the accessibility of potentially lifesaving treatments. Overall, these leaders are advancing efforts to eliminate neglected tropical diseases and enhance the global health experience.

Neglected Tropical Disease Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments

• In November 2024, African countries, under the leadership of the Africa Centers for Disease Control and Prevention (Africa CDC), endorsed a new continental strategic plan as a blueprint to tackle endemic and neglected tropical diseases across Africa. Delegates from all AU members came together to review and approve the continental blueprint for 2024-2027 aimed at combating endemic and neglected tropical diseases, according to a statement issued by the Africa CDC.
• In September 2024, The Bill & Melinda Gates Foundation announced four grants totaling $68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable millions of people in the world’s poorest countries every year. One of the grants will support a new medical journal devoted to neglected diseases.

Report Coverage:

 By Treatment Type

• Drug Therapy
  • Antiparasitic
  • Antifungals
  • Antiviral Agents
  • Antibiotics
• Vaccination
• Combination Therapy
• Symptomatic Treatment
• Supportive Therapies

By Disease Type

• Dengue
• Chagas Disease
• Leishmaniasis
• Lymphatic Filariasis
• Schistosomiasis
• Human African Trypanosomiasis
• Onchocerciasis
• Rabies
• Soil-transmitted Helminths (STH)
• Other

 By Route of Administration

• Oral
• Parenteral
• Topical

By End-User

• Hospitals
• Clinics
• Research Institutes
• Non-Governmental Organizations (NGOs)

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• GlaxoSmithKline plc
• Pfizer Inc.
• Sanofi
• Novartis AG
• Bayer AG
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Eisai Co., Ltd.
• Boehringer Ingelheim
• Takeda Pharmaceutical Company Limited
• Shionogi & Co., Ltd.
• Dr. Reddy's Laboratories
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Zydus Cadila
• Mylan N.V.
• Gilead Sciences, Inc.

Frequently Asked Questions (FAQs)